Services

Medicinal Chemistry

Primary screening studies initially generate a list of compounds with the required biological activities (‘Hits’). These Hits rarely fulfil all the criteria for a quality “tool” compound as they typically show only a moderate affinity for the target and restricted selectivity.

To become a useful tool compound, the chemical properties of the initial Hits must therefore be iteratively improved by suitable structural modification. The post-screening Hit-to-tool optimisation process is carried out by accredited chemistry partner sites in EU-OPENSCREEN ERIC Member countries and is organised as a research collaboration between the assay provider and the respective chemistry site.

Apply for funding

Currently, the European Commission offers project funding for medicinal chemistry support in our EU-OPENSCREEN ERIC partner sites through the ISIDORe project. Read more here.

  

 

Medicinal chemistry partner sites

CZECH REPUBLIC


Masaryk University (MU) – Laboratory of Organic Synthesis and Medicinal Chemistry

Dr. Kamil Paruch

Information PDF

Germany


Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) – Medicinal Chemistry

Dr. Marc Nazaré

Information PDF​​​​​​​

LATVIA


Latvian Institute of Organic Synthesis (LIOS)

Dr. Osvalds Pugovičs

Information PDF​​​​​​​

POLAND


Institute of Biochemistry and Biophysics (IBB PAS)

Prof. Dr. Piotr Zielenkiewicz

Information PDF

PORTUGAL


University of Lisbon - Research Institute for Medicines (iMed.ULisboa)

Rui Moreira

rmoreira@ff.ulisboa.pt

 

University of Porto - Chemistry Research Centre (FCUP)

Fernanda Borges

fborges@fc.up.pt

SPAIN


Center for Biological Research Margarita Salas (CSIC)

Prof. Dr. Ana Martínez

Information PDF

SWEDEN


Karolinska Institutet - Department Medical Biochemistry and Biophysics (CBCS-KI)

Anna-Lena Gustavsson

anna-lena.gustavsson@ki.se

 

Umeå University - Chemical Biology Centre (CBCS-UmU)

Erik Chorell

Erik.chorell@umu.se